Neuropsychobiology · 2008 · 29 citations · 9 references
MedicinePharmacologyPsychiatryClinical PharmacologyNeuropharmacologyPsychopharmacologyAnxiety Disorder PharmacotherapyAnxiety DisordersAnxiety SymptomsAnxiolytic PharmacologyAnxiolytic PharmacotherapyAnxiolytic TherapyAnxiolytic Medication UseAnxiolytic MedicationsAssessmentsBuspirone PharmacologyDouble-blind TrialsPharmacologic AnxiolysisRebound AnxietyWithdrawal Symptoms
The anxiolytic activity, the tolerance, and the withdrawal symptoms of buspirone and oxazepam were compared in two groups of 14 and 12 outpatients, respectively, suffering from generalized anxiety in a double-blind study with random allocation of patients. The 6-week active period was preceded and followed by 1 and 2 weeks on placebo, respectively. Clinical assessments were performed before and after the predrug placebo period and every 2 weeks thereafter and included Hamilton anxiety and depression scales and AMDP anxiety subscale. The initial daily dose was 15 mg buspirone or 45 mg oxazepam in 3 intakes and the mean final daily doses were 22.2 and 55.8 mg, respectively. Results showed a slower anxiolytic activity of buspirone compared to oxazepam with less improvement after 2 weeks of treatment. The rebound anxiety following abrupt discontinuation of the drug and the level of side effects did not significantly differ between the two compounds.
9
M. Hamilton · Journal of Neurology Neurosurgery & Psychiatry · 1960 · 32.6K citations · Full text
Open trial of buspirone in the treatment of major depressive disorder.
Schweizer Ee, Jay D. Amsterdam, Karl Rickels et al. · PubMed · 1986 · 85 citations
Medicine, Pharmacology, Psychiatry +13
Buspirone: multicenter efficacy study.
Daniel Wheatley · PubMed · 1982 · 83 citations